Cleveland Clinic study finds it’s safe and effective
Enroll patients now in KEYNOTE-630 trial
Study findings presented at ASCO 2019
Another option for immunotherapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Will we see this major breakthrough in 2019?
Daratumumab is effective and safe
Gene expression analysis uncovers clues
Novel drugs included in therapy
Test helpful for SLN-negative, stage I to IIA and thin tumors
Refractory patients respond to combination therapy
Advertisement
Advertisement